Home/Filings/4/0001104659-22-011081
4//SEC Filing

Dudley Robert Michael 4

Accession 0001104659-22-011081

CIK 0001829635other

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 6:03 AM ET

Size

5.7 KB

Accession

0001104659-22-011081

Insider Transaction Report

Form 4
Period: 2022-02-01
Dudley Robert Michael
DirectorChief Executive Officer10% Owner
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-02-01+135,000135,000 total
    Exercise: $2.45Exp: 2031-01-31Common Stock (135,000 underlying)
Footnotes (1)
  • [F1]Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.

Issuer

Transcode Therapeutics, Inc.

CIK 0001829635

Entity typeother

Related Parties

1
  • filerCIK 0001854161

Filing Metadata

Form type
4
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 6:03 AM ET
Size
5.7 KB